Beijing YST

Beijing YST Pharmaceutical Technology is a specialized biotechnology company based in China that focuses on the research and development of long-acting injectable formulations. The company utilizes a proprietary microsphere technology platform to develop sustained-release versions of established therapeutic agents, aiming to enhance patient adherence and clinical efficacy. Its primary pipeline candidates target central nervous system disorders and metabolic diseases, including long-acting treatments for schizophrenia and diabetes. Beijing YST provides both internal drug development and technical services related to complex formulation challenges. The company's lead program, YST-001, is a long-acting risperidone formulation currently in clinical development. By bridging the gap between innovative delivery science and clinical needs, Beijing YST seeks to improve the management of chronic conditions.